HMGB1 and neoplasm: In addition, several biomarkers are associated with tumor-promoting signaling pathways and adverse clinical outcomes; for instance, cathepsin D, miR-421, and HMGB1 are frequently overexpressed in osteosarcoma and linked to enhanced tumor progression.